Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Receives $96.58 Average Price Target from Brokerages
Shares of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI – Get Free Report) have earned an average rating of “Moderate Buy” from the twelve research firms that are currently covering the firm, Marketbeat.com reports. Two research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company. The average 12-month […]
More Stories
Top 10 Investment Accounting Software & Other Related Software
Managing complex investment portfolios can be hectic most of the time, as a small mistake can lead to a huge...
Top 10 Richest K-Pop Idols in 2026
Do you also like K-pop or Korean pop? Then this article is for you. Let’s start. In this blog, you...
Over-the-Counter Medicines, Other Items Recalled Over Feces Contamination: FDA
By Jack Phillips The U.S. Food and Drug Administration (FDA) late last week announced that a distributor is recalling its...
Iranian President Says His Country in ‘Full-Fledged War’ With US, Europe, and Israel
By Jack Phillips Iranian President Masoud Pezeshkian said Saturday that the Iranian regime is in a full-scale war with the...
US Airline Industry Caps a Strong 2025—What Lies Ahead in 2026
By Panos Mourdoukoutas Despite a shaky start earlier in the year, U.S. airline travel reached another milestone during the 2025...
What Trump’s National Security Strategy Means for Canada
By Noe Chartier Canada receives but a passing mention in the recently released U.S. National Security Strategy, but that doesn’t...